Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
No company officers listed.
No insider trading activity.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.